Clinical trial data published in The New England Journal of Medicine showed the PRIMA wireless photovoltaic retinal implant restored reading vision for some patients with geographic atrophy from advanced age‑related macular degeneration. The device, paired with augmented‑reality glasses, enabled unprecedented reading gains in selected participants. Court filings show Science Corporation acquired the program’s assets at fire‑sale prices after Pixium Vision’s financial distress; Science now seeks regulatory approvals in Europe and is in talks with U.S. regulators. Investigators, including José‑Alain Sahel, highlighted the magnitude of visual improvement in several patients. The ownership shift and fresh clinical evidence compress timelines for regulatory strategy and commercialization planning while prompting scrutiny of manufacturing scale, reimbursement pathways and long‑term durability data.